Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**KY88 Liver Livo** is a multi-herb traditional Chinese medicine preparation containing *Radix Bupleuri* and described in the literature as a blend of 10 herbal extracts. In cell-based studies, a methanol extract inhibited proliferation of HB8064 hepatocellular carcinoma cells in a dose-dependent manner and produced DNA-laddering consistent with apoptosis; increased interleukin-4 and tumor necrosis factor-alpha were also reported. Separate in-vitro work found lymphocyte stimulation and dose-dependent granulocyte-macrophage colony-stimulating factor secretion. These are preclinical and laboratory observations; no defined molecular target, standardized composition, regulatory approval, or clinical development program was identified. ([europepmc.org](https://europepmc.org/article/MED/15315257))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KY88 Liver Livo.